Abstract:Primary liver cancer accounts for the third most deadly type of malignant tumor globally, and approximately 80% of the cases are hepatocellular carcinoma (HCC), which highly relies on the activity of hypoxia responsive pathways to bolster its metastatic behaviors. MicroRNA-29a (MIR29A) has been shown to exert a hepatoprotective effect on hepatocellular damage and liver fibrosis induced by cholestasis and diet stress, while its clinical and biological role on the activity hypoxia responsive genes including LOX, LOXL2, and VEGFA remains unclear. TCGA datasets were retrieved to confirm the differential expression and prognostic significance of all genes in the HCC and normal tissue. The Gene Expression Omnibus (GEO) dataset was used to corroborate the differential expression and diagnostic value of MIR29A. The bioinformatic identification were conducted to examine the interaction of MIR29A with LOX, LOXL2, and VEGFA. The suppressive activity of MIR29A on LOX, LOXL2, and VEGF was verified by qPCR, immunoblotting, and luciferase. The effect of overexpression of MIR29A-3p mimics in vitro on apoptosis markers (caspase-9, -3, and poly (ADP-ribose) polymerase (PARP)); cell viability and wound healing performance were examined using immunoblot and a WST-1 assay and a wound healing assay, respectively. The HCC tissue presented low expression of MIR29A, yet high expression of LOX, LOXL2, and VEGFA as compared to normal control. Serum MIR29A of HCC patients showed decreased levels as compared to that of normal control, with an area under curve (AUC) of 0.751 of a receiver operating characteristic (ROC) curve. Low expression of MIR29A and high expression of LOX, LOXL2, and VEGFA indicated poor overall survival (OS). MIR29A-3p was shown to target the 3′UTR of LOX, LOXL2, and VEGFA. Overexpression of MIR29A-3p mimic in HepG2 cells led to downregulated gene and protein expression levels of LOX, LOXL2, and VEGFA, wherein luciferase reporter assay confirmed that MIR29A-3p exerts the inhibitory activity via directly binding to the 3′UTR of LOX and VEGFA. Furthermore, overexpression of MIR29A-3p mimic induced the activity of caspase-9 and -3 and PARP, while it inhibited the cell viability and wound healing performance. Collectively, this study provides novel insight into a clinical-applicable panel consisting of MIR29, LOX, LOXL2, and VEGFA and demonstrates an anti-HCC effect of MIR29A via comprehensively suppressing the expression of LOX, LOXL2, and VEGFA, paving the way to a prospective theragnostic approach for HCC.

MicroRNA‑29c‑3p Acts As a Tumor Suppressor Gene and Inhibits Tumor Progression in Hepatocellular Carcinoma by Targeting TRIM31

miR-30 functions as a tumor suppressor by modulating CD90 in hepatocellular carcinoma

MiR-29a Suppresses Cell Proliferation by Targeting SIRT1 in Hepatocellular Carcinoma

MicroRNA-302d Downregulates TGFBR2 Expression and Promotes Hepatocellular Carcinoma Growth and Invasion.

Microrna-29b Suppresses Tumor Angiogenesis, Invasion, and Metastasis by Regulating Matrix Metalloproteinase 2 Expression

MicroRNA-30a-3p inhibits tumor proliferation, invasiveness and metastasis and is downregulated in hepatocellular carcinoma.

TRIM29 modulates proteins involved in PTEN/AKT/mTOR and JAK2/STAT3 signaling pathway and suppresses the progression of hepatocellular carcinoma

MIR29A Impedes Metastatic Behaviors in Hepatocellular Carcinoma via Targeting LOX, LOXL2, and VEGFA

MicroRNA-627-5p inhibits the proliferation of hepatocellular carcinoma cells by targeting BCL3 transcription coactivator.

miR-29c targets TNFAIP3, inhibits cell proliferation and induces apoptosis in hepatitis B virus-related hepatocellular carcinoma.

MiR-30b-5p Acts As a Tumor Suppressor, Repressing Cell Proliferation and Cell Cycle in Human Hepatocellular Carcinoma.

Mir-654-3p Predicts the Prognosis of Hepatocellular Carcinoma and Inhibits the Proliferation, Migration, and Invasion of Cancer Cells

Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma.

MicroRNA‑875‑5p Inhibits Tumor Growth and Metastasis of Hepatocellular Carcinoma by Targeting Eukaryotic Translation Initiation Factor 3 Subunit A.

MicroRNA-197-3p Acts As a Prognostic Marker and Inhibits Cell Invasion in Hepatocellular Carcinoma

Microrna-363-3p Inhibits Hepatocarcinogenesis By Targeting Hmga2 And Is Associated With Liver Cancer Stage

Hsa_circ_0026134 Expression Promoted TRIM25- and IGF2BP3-mediated Hepatocellular Carcinoma Cell Proliferation and Invasion Via Sponging Mir-127-5p

MicroRNA-30a Suppresses Tumor Progression by Blocking Ras/Raf/MEK/ERK Signaling Pathway in Hepatocellular Carcinoma.

MiR-299-3p Functions As a Tumor Suppressor Via Targeting Sirtuin 5 in Hepatocellular Carcinoma

MicroRNA‐301b‐3p Contributes to Tumour Growth of Human Hepatocellular Carcinoma by Repressing Vestigial Like Family Member 4

MicroRNA-140-5p suppresses tumor growth and metastasis by targeting transforming growth factor β receptor 1 and fibroblast growth factor 9 in hepatocellular carcinoma.